Changes in prescription patterns of oral contraceptives in a northern Italian province: Relation with venous thromboembolism

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 2, 2003, Pages 125-130

  Girolami, Antonio ^a   Spiezia, Luca ^a   Vianello, Fabrizio ^a   Girolami, Bruno ^a   Fabris, Fabrizio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Oral contraceptives; Progestins; Venous thromboembolism

Indexed keywords

GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; THROMBOEMBOLISM; VEIN DISEASE;

EID: 0038386101     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900206     Document Type: Article

References (37)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575.
2. Helmrich SP, Rosemberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987;69:91.
3. Vessey M, Mant D, Smith A, Yeats D. Oral contraceptives and venous thromboembolism: Finding in a large prospective study. BMJ 1986;292:526.
4. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527.
5. Weiss G. Risk of venous thromboembolism with third-generation oral contraceptives: A review. Am J Obstet Gynecol 1999;180:295.
6. Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998;57:169.
7. Girolami A, Simioni P, Zanardi S. The role of drugs, particularly oral contraceptives in triggering thrombosis in congenital defects of coagulation inhibitors: A study of six patients. Blood Coagul Fibrinolysis 1991;2:673.
8. Girolami A, Stevanato F, Lazzaro AR. Bilateral ileofemoral thrombophlebitis after ten contraceptive pills in a 25-year-old woman with antithrombin III deficiency. Acta Haematol 1988;79:118.
9. Girolami A, Simioni P, Sartori MT, Zanardi S. Oral contraceptives caused thrombosis in a monoovular twin protein C deficiency, while the other, without medication, remained asymptomatic. Blood Coagul Fibrinolysis 1992;3:119.
10. Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study. Blood 1999;94:3702.
11. Girolami A, Simioni P, Scarano L, Zanardi S, Girolami B. Patient with APC-resistance as compared with other clotting inhibitor deficiencies show a later onset of venous thrombosis during oral contraception. Clin Appl Thromb Hemost 1995;1:118.
12. Girolami A, Tormene D, Vianello F. Prothrombotic activity of oral contraceptives in patients with congenital thrombophilia varies with the defect. Clin Appl Thromb Hemost 2001;7:76.
13. Girolami A, Simioni P, Girolami B, Radossi P. Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception. Blood Coagul Fibrinolysis 1996;7:590.
14. Girolami A, Simioni P, Tormene D. APC resistance, oral contraceptive therapy and deep vein thrombosis: Settled and unsettled problems. Haematologica 2000;85:225.
15. Girolami A, Tormene D, Simioni P, Zanon E. Long-term use of oral contraceptive therapy in women with the prothrombin 20210 g-a polymorphism without thrombotic complications: A study of 13 women (12 heterozygotes and 1 homozygote). Thromb Res 2001;102:205.
16. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999;19:700.
17. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582.
18. Committee on Safety of Medicine: Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. Curr Probl Pharmacovig 1999;25:12.
19. Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: Risk of venous thromboembolism. Thromb Haemost 1997;78:327.
20. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589.
21. Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998;57:211.
22. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83.
23. Farmer RD, Williams TJ, Simpson EL, Nightingale AL. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: Analysis of general practice research database. BMJ 2000;321:477.
24. O'Brien PA. The third generation oral contraceptive controversy. The evidence shows they are less safe than second generation pills. BMJ 1999;319:795.
25. Farley TM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: Reviewing the evidence and balancing the risks. Hum Reprod Update 1999;5:721.
26. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83.
27. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141.
28. Kluft C. Renewed interest in haemostasis changes induced by oral contraceptives (OCs). Thromb Haemost 2000;84:1.
29. Greaves M, Preston FE. Rebuttal to: Oral contraceptives and venous thromboembolism. Thromb Haemost 2001; 85:932.
30. Skegg DCG. Third generation oral contraceptives. BMJ 2000;321:190.
31. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787.
32. Girolami A, Spiezia L, Rossi F, Zanon E. Oral contraceptive and venous thromboembolism: Which are the safest preparation available. Clin Appl Thromb Haemost 2002;8:157.
33. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1.
34. Carter CJ. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis 1994;36:423.
35. European Agency for the Evaluation of medicinal products. Combined oral contraceptives and venous thromboembolism. N° 2001/01, Sept. 2001. Available at http://www.emea.eu.int/pdfs/human/regaffair/0220101 en.pdf.
36. Girolami A, Spiezia L, Girolami B, Vianello F. Tentative guidelines and practical suggestions in order to avoid venous thromboembolism during oral contraceptive therapy. Clin Appl Thromb Haemost 2002;8:97.
37. Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: Review of studies on cardiovascular disease and use of combined oral contraceptives. BMJ 1998;316:984.